Written by Mark Houston, MD, and Sara Gottfried, MD
High-density lipoprotein (HDL) plays a vital role in lipid biology and coronary heart disease (CHD) pathophysiology. However, we’re witnessing a major paradigm shift in the medical community regarding the role of HDL-cholesterol (HDL-C) in dyslipidemia and dyslipidemia-induced cardiovascular disease, especially CHD and myocardial infarction (MI). (4)
What is HDL?
HDLs are complex nanoparticles with more than 80 associated proteins, phospholipids, cholesterol, and cholesteryl esters. HDL is best known for its ability to scavenge for and ferry low-density lipoprotein cholesterol (LDL-C) away from the arteries and back to the liver for redistribution, metabolism, and elimination. (4)
HDL: the paradigm shift in the role
LDL is essentially a “garbage”-type particle that deposits cholesterol in cells all over the body, while HDL is like a “garbage” collector. The HDL particle literally takes excess cholesterol out of tissue to remove it from the body, usually through the liver. (4)
Epidemiological studies, ranging from the Framingham Study and continuing through to the Atherosclerosis Risk in Communities (ARIC) Study, demonstrated that HDL-C is inversely associated with CHD and MI. (9)(30) Specifically, as the calculation was extended, CHD risk increased by 3% in men and 2% in women for every 1 mg/dL decrement in HDL-C. (8) Patients were told high HDL-C meant high “reverse cholesterol transport (RCT),” the body’s ability to bring cholesterol back to the liver for removal. It was believed that as long as HDL-C levels were above a threshold, a patient was protected from having CHD and/or MI.
New research compels us to update that perception, as evidence points to a more nuanced model. Pharmacological interventions in randomized trials that raise HDL-C by two- to threefold have failed to produce the anticipated reduction in cardiovascular risk. (2)(1)(29)(12)(7) Additionally, HDL-associated apolipoprotein A-I (apoA-I) levels in HDL subtypes are a better predictor of cardiovascular risk than HDL-C concentration. (35) The anti-atherogenic capacity of HDL seems to be mediated by function, such as cholesterol efflux capacity (CEC), which is a superior predictor of risk than total HDL-C concentration, (22) though not all data are concordant. Data from genome-wide association studies (GWAS) show that lower HDL-C may not cause CHD, high HDL-C may not be protective from CHD, and heterogeneity of HDL structure and function may be more to blame. (34)(33)
In other words, if HDL is the garbage collector, there’s a range of options in the fleet. Some garbage trucks look good but don’t perform. Some have flat tires. But some of the garbage trucks are top of the line, some have large carrying capacity, others have small carrying capacity, and others are highly dependable and perform beyond expectations—that’s the spectrum of HDL function.
We can no longer rely on high HDL-C alone for heart health protection because experts are now questioning the composition and function of the various types of HDL.
What is HDL function?
Static measurement of HDL-C fails to reflect the dynamics of the HDL particle, its remodeling process, the HDL cargo load, HDL interconversions in the lipid pathway, the hepatic unloading, and resulting function.
Until recently HDL function could not be measured. We only had “indicative markers of HDL function,” such as myeloperoxidase (MPO) and inflammatory and oxidative stress markers, but not direct assessments of HDL function. However, a new lab in beta testing may soon be available to measure to determine HDL function simply. Investigators demonstrated that assessment of CEC is one metric of HDL function and may in fact be a predictor of atherosclerosis and cardiovascular disease risk. (6)
New research is painting a broader picture that HDL function may be impaired by systemic inflammation or oxidative stress, such as that from autoimmunity, suggesting that improvement in HDL function may help beyond cardiovascular risk. (17)
HDL mapping of various subspecies of HDL
There are five forms of HDL particles. “HDL mapping” is a test which includes α-1, α-2, α-3, α-4, and pre-β HDL. Emphasis on the importance was placed on large HDLs such as α-1 and, to a degree, α -2. This concept has since changed. Small HDL may be just as important as they transform into larger HDL, which removes more LDL. All types of HDL may play a role in this process.
But without proper function, even size doesn’t matter. A patient may have a normal level of all HDL sizes with HDL mapping, but his HDL function can be abnormal. Think of it like a garbage truck with four flat tires. That’s why function is the key factor. (27)
The importance of HDL particle number
The benefits of HDL also depend on the number of HDL particles. This is called HDL particle number (HDL-P). Based on recent research, the higher the HDL particle number, the more protected the person is from CHD and MI. (16) Many researchers agree HDL function and particle number are the two most important factors when measuring HDL. In fact, in many studies, the HDL-P and HDL function measurements are equally predictive of CHD and MI.
Nutritional protocol for HDL function
Supplementation can play a key role in HDL management. There are very few pharmaceutical agents that modify HDL. Most won‘t affect the lab parameters we’ve covered. However, various nutraceutical supplement and nutritional changes can modify at least one of these key factors.
Variety of foods
Increased intake of virgin olive oil, nuts, legumes, whole grains, and fish improves HDL function. (11) Specifically, olive oil and whole-grain consumption raise CEC. Nut and legume intake improve PON-1 activity. Legumes decrease cholesteryl ester transfer protein activity. Fish consumption increases PON-1 activity and declines in cholesteryl ester transfer protein activity, HDL-C concentrations, and functions related to HDL (CEC).
Green tea extract
Flavonoids, such as anthocyanin, positively change serum biomarkers related to HDL function in several patient populations, including dyslipidemic, hypertensive, and diabetic individuals. This results in not only increased HDL cholesterol levels, but also HDL anti-oxidant and CEC. (19)
Additional bioactives for HDL function
Track patient progress
As HDL-C provides almost no information on HDL function, other measurements are needed to track whether interventions are effective. Biomarkers of low-grade inflammation (e.g., hs-CRP) and oxidative stress (MPO) give information on HDL particle dysfunction risk. Advanced lipid panels (e.g., HDL-P) and HDL mapping provide additional information on the health of HDL particles. Patients’ results will guide or alter a supplement and lifestyle protocol. Close follow-up and repeat testing should be run every two to four months. When a patient achieves optimal levels of all three components, a reduction in the event rate for CHD and MI should be seen. (14)
The bottom line
The latest discoveries on the key parameters of HDL efficiency have led to promising new treatment methods for better patient outcomes. Recognizing and measuring HDL type, size, function, and particle number are key factors in protecting patients from CHD and MIs. Through proper nutrition and lifestyle protocols, we can better protect our patient populations from the perils of heart-related health concerns.
Disclosure: This article was written in partnership with Metagenics. All supplier partnerships have been approved by doctors on our Integrative Medical Advisory team, and this content adheres to all guidelines outlined in our content philosophy. Fullscript has not been compensated financially for the publication of this article.
- AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. (2011, Dec 15). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine, 365(24), 2255-2267.
- Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. (2007, Nov 22). Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine, 357(21), 2109-2122.
- Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, Aston CE, Lyons TJ. (2010, Feb). Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. Journal of the American College of Nutrition, 29(1):31-40.
- Chiesa, S. T., & Charakida, M. (2019). High-Density Lipoprotein Function and Dysfunction in Health and Disease. Cardiovascular drugs and therapy, 33(2), 207–219.
- Darabi M, Kontush A. (2016, Jan). Can phosphatidylserine enhance atheroprotective activities of high-density lipoprotein? Biochimie, 120, 81-86.
- Favari E, Thomas MJ, Sorci-Thomas MG. (2018). High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis. Journal of Cardiovascular Pharmacology, 71, 325-331.
- Ferri N, Corsini A, Sirtori CR, Ruscica M. (2018, Feb). Present therapeutic role of cholesteryl ester transfer protein inhibitors. Pharmacological Research, 128, 29-41.
- Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. (1989, Jan). High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79(1), 8-15.
- Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. (1977). High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. The American Journal of Medicine, 62, 707-714.
- Hamoud S, Hayek T, Volkova N, Attias J, Moscoviz D, Rosenblat M, Aviram M. (2014, Jan). Pomegranate extract (POMx) decreases the atherogenicity of serum and of human monocyte-derived macrophages (HMDM) in simvastatin-treated hypercholesterolemic patients: a double-blinded, placebo-controlled, randomized, prospective pilot study. Atherosclerosis, 232(1), 204-210.
- Hernáez Á, Sanllorente A, Castañer O, Martínez-González MÁ, Ros E, Pintó X, Estruch R, Salas-Salvadó J, Corella D, Alonso-Gómez ÁM, Serra-Majem L, Fiol M, Lapetra J, Gómez-Gracia E, de la Torre R, Lamuela-Raventós RM, Fitó M. (2019, Mar). Increased Consumption of Virgin Olive Oil, Nuts, Legumes, Whole Grains, and Fish Promotes HDL Functions in Humans. Molecular Nutrition & Food Research, 63(6), e1800847.
- HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. (2014, Jul 17). Effects of extended-release niacin with laropiprant in high-risk patients. New England Journal of Medicine, 371(3), 203-212.
- Khera AV, Patel PJ, Reilly MP, Rader DJ. (2013, Nov 12). The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. Journal of the American College of Cardiology, 62(20), 1909-1910.
- Khera, A. V., Demler, O. V., Adelman, S. J., Collins, H. L., Glynn, R. J., Ridker, P. M., Rader, D. J., & Mora, S. (2017). Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation, 135(25), 2494–2504.
- Kontush A, Chapman MJ. (2006). Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacological Reviews, 58, 342-374.
- Kontush A. (2015, Oct 5).HDL particle number and size as predictors of cardiovascular disease. Frontiers in Pharmacology, 6, 218.
- Macpherson ME, Halvorsen B, Yndestad A, Ueland T, Mollnes TE, Berge RK, Rashidi A, Otterdal K, Gregersen I, Kong XY, Holven KB, Aukrust P, Fevang B, Jørgensen SF. (2019, Jul 1). Impaired HDL Function Amplifies Systemic Inflammation in Common Variable Immunodeficiency. Scientific Reports, 9(1), 9427.
- McEneny J, Wade L, Young IS, Masson L, Duthie G, McGinty A, McMaster C, Thies F. (2013, Jan). Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. Journal of Nutritional Biochemistry, 24(1), 163-168.
- Millar CL, Duclos Q, Blesso CN. (2017, Mar 15). Effects of Dietary Flavonoids on Reverse Cholesterol Transport, HDL Metabolism, and HDL Function. Advances in Nutrition, 8(2), 226-239.
- Morgan JM, de la Llera-Moya M, Capuzzi DM. (2007). Effects of niacin and Niaspan on HDL lipoprotein cellular SR-BI-mediated cholesterol efflux. Journal of Clinical Lipidology, 1, 614-619.
- Newton-Cheh C, Musunuru K, Pirruccello JP, … Kathiresan S. (2012, Aug 11). Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet, 380(9841), 572-580.
- Qiu C, Zhao X, Zhou Q, Zhang Z. (2017, Nov 10). High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis. Lipids in Health Disease, 16(1), 212.
- Ren K, Jiang T, Zhao GJ. (2018, Jan 24). Quercetin induces the selective uptake of HDL-cholesterol via promoting SR-BI expression and the activation of the PPARγ/LXRα pathway. Food & Function, 9(1), 624-635.
- Riccioni G, Gammone MA, Currenti W, D’Orazio N. (2018, May 14).Effectiveness and Safety of Dietetic Supplementation of a New Nutraceutical on Lipid Profile and Serum Inflammation Biomarkers in Hypercholesterolemic Patients. Molecules, 23(5).
- Ronsein, G. E., Hutchins, P. M., Isquith, D., Vaisar, T., Zhao, X. Q., & Heinecke, J. W. (2016). Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects. Arteriosclerosis, thrombosis, and vascular biology, 36(2), 404–411.
- Rosenblat M, Volkova N, Khatib S, Mahmood S, Vaya J, Aviram M. (2014, Dec). Reduced glutathione increases quercetin stimulatory effects on HDL- or apoA1-mediated cholesterol efflux from J774A.1 macrophages. Free Radical Research, 48(12), 1462-1472.
- Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013 Sep 10;128(11):1256-67.
- Rock W, Rosenblat M, Miller-Lotan R, Levy AP, Elias M, Aviram M. (2008, Sep 24). Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. Journal of Agricultural and Food Chemistry, 56(18), 8704-8713.
- Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators. (2012, Nov 29). Effects of dalcetrapib in patients with a recent acute coronary syndrome. New England Journal of Medicine, 367(22), 2089-2099.
- Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W; Atherosclerosis Risk in Communities Study Group. (2001, Sep 4). Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 104(10), 1108-1113.
- Shidfar F, Froghifar N, Vafa M, Rajab A, Hosseini S, Shidfar S, Gohari M. (2011, May). The effects of tomato consumption on serum glucose, apolipoprotein B, apolipoprotein A-I, homocysteine and blood pressure in type 2 diabetic patients. International Journal of Food Sciences and Nutrition, 62(3), 289-294.
- Toth, P. P., Thakker, K. M., Jiang, P., & Padley, R. J. (2012). Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. Vascular health and risk management, 8, 39–44.
- Vitali C, Khetarpal SA, Rader DJ. (2017, Nov 4). HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics. Current Cardiology Reports, 19(12), 132.
- Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., Schunkert, H., Samani, N. J., Clarke, R., Hopewell, J. C., Thompson, J. F., Li, M., Thorleifsson, G., Newton-Cheh, C., Musunuru, K., Pirruccello, J. P., … Kathiresan, S. (2012). Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (London, England), 380(9841), 572–580.
- Walldius G, Jungner I. (2007, Jul). Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Current Opinion in Cardiology, 22(4), 359-367.
- Wang S, Moustaid-Moussa N, Chen L, Mo H, Shastri A, Su R, Bapat P, Kwun I, Shen CL. (2014, Jan). Novel insights of dietary polyphenols and obesity. Journal of Nutritional Biochemistry, 25(1), 1-18.